INBRIJA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Inbrija, and what generic alternatives are available?
Inbrija is a drug marketed by Acorda and is included in one NDA. There are six patents protecting this drug.
This drug has one hundred and three patent family members in twenty-two countries.
The generic ingredient in INBRIJA is levodopa. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the levodopa profile page.
DrugPatentWatch® Generic Entry Outlook for Inbrija
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be November 16, 2032. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for INBRIJA
International Patents: | 103 |
US Patents: | 6 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 134 |
Patent Applications: | 4,218 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for INBRIJA |
What excipients (inactive ingredients) are in INBRIJA? | INBRIJA excipients list |
DailyMed Link: | INBRIJA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for INBRIJA
Generic Entry Date for INBRIJA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INHALATION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for INBRIJA
Drug Class | Aromatic Amino Acid |
Anatomical Therapeutic Chemical (ATC) Classes for INBRIJA
US Patents and Regulatory Information for INBRIJA
INBRIJA is protected by six US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of INBRIJA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting INBRIJA
Particulate compositions for pulmonary delivery
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Capsules containing high doses of levodopa for pulmonary use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Capsules containing high doses of levodopa for pulmonary use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Capsules containing high doses of levodopa for pulmonary use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Capsules containing high doses of levodopa for pulmonary use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pulmonary delivery for levodopa
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for INBRIJA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | ⤷ Sign Up | ⤷ Sign Up |
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | ⤷ Sign Up | ⤷ Sign Up |
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | ⤷ Sign Up | ⤷ Sign Up |
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | ⤷ Sign Up | ⤷ Sign Up |
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for INBRIJA
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Acorda Therapeutics Ireland Limited | Inbrija | levodopa | EMEA/H/C/004786 Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. |
Authorised | no | no | no | 2019-09-19 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for INBRIJA
When does loss-of-exclusivity occur for INBRIJA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 13342246
Estimated Expiration: ⤷ Sign Up
Patent: 13342247
Estimated Expiration: ⤷ Sign Up
Patent: 13342248
Estimated Expiration: ⤷ Sign Up
Patent: 17279626
Estimated Expiration: ⤷ Sign Up
Patent: 18204674
Estimated Expiration: ⤷ Sign Up
Patent: 18222983
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2015010601
Estimated Expiration: ⤷ Sign Up
Patent: 2015010603
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 90451
Estimated Expiration: ⤷ Sign Up
Patent: 90454
Estimated Expiration: ⤷ Sign Up
Patent: 90459
Estimated Expiration: ⤷ Sign Up
China
Patent: 4918607
Estimated Expiration: ⤷ Sign Up
Patent: 5120843
Estimated Expiration: ⤷ Sign Up
Patent: 9106697
Estimated Expiration: ⤷ Sign Up
Patent: 0833539
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 16821
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 16821
Estimated Expiration: ⤷ Sign Up
Patent: 16826
Estimated Expiration: ⤷ Sign Up
Patent: 25611
Estimated Expiration: ⤷ Sign Up
Patent: 15679
Estimated Expiration: ⤷ Sign Up
Patent: 57301
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 12884
Estimated Expiration: ⤷ Sign Up
Patent: 13186
Estimated Expiration: ⤷ Sign Up
Patent: 13187
Estimated Expiration: ⤷ Sign Up
Patent: 13535
Estimated Expiration: ⤷ Sign Up
Patent: 14957
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 47786
Estimated Expiration: ⤷ Sign Up
Patent: 48501
Estimated Expiration: ⤷ Sign Up
Patent: 69808
Estimated Expiration: ⤷ Sign Up
Patent: 21629
Estimated Expiration: ⤷ Sign Up
Patent: 36834
Estimated Expiration: ⤷ Sign Up
Patent: 15536197
Estimated Expiration: ⤷ Sign Up
Patent: 15536988
Estimated Expiration: ⤷ Sign Up
Patent: 15536989
Estimated Expiration: ⤷ Sign Up
Patent: 18150355
Estimated Expiration: ⤷ Sign Up
Patent: 18162258
Estimated Expiration: ⤷ Sign Up
Patent: 19213867
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 1008
Estimated Expiration: ⤷ Sign Up
Patent: 15005767
Estimated Expiration: ⤷ Sign Up
Patent: 15005768
Estimated Expiration: ⤷ Sign Up
Patent: 20012506
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 8682
Estimated Expiration: ⤷ Sign Up
Patent: 8684
Estimated Expiration: ⤷ Sign Up
Patent: 3459
Estimated Expiration: ⤷ Sign Up
Patent: 7376
Estimated Expiration: ⤷ Sign Up
Patent: 7378
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 16821
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 16821
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 70987
Estimated Expiration: ⤷ Sign Up
Patent: 76093
Estimated Expiration: ⤷ Sign Up
Patent: 15121091
Estimated Expiration: ⤷ Sign Up
Patent: 15121092
Estimated Expiration: ⤷ Sign Up
Patent: 18144622
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201706465X
Estimated Expiration: ⤷ Sign Up
Patent: 201707103S
Estimated Expiration: ⤷ Sign Up
Patent: 202109328Q
Estimated Expiration: ⤷ Sign Up
Patent: 201503543P
Estimated Expiration: ⤷ Sign Up
Patent: 201503547T
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1504058
Estimated Expiration: ⤷ Sign Up
Patent: 1504060
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2257164
Estimated Expiration: ⤷ Sign Up
Patent: 2337781
Estimated Expiration: ⤷ Sign Up
Patent: 2389785
Estimated Expiration: ⤷ Sign Up
Patent: 150108816
Estimated Expiration: ⤷ Sign Up
Patent: 150110480
Estimated Expiration: ⤷ Sign Up
Patent: 210062730
Estimated Expiration: ⤷ Sign Up
Patent: 210152020
Estimated Expiration: ⤷ Sign Up
Patent: 220054703
Estimated Expiration: ⤷ Sign Up
Patent: 230116102
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 44153
Estimated Expiration: ⤷ Sign Up
Patent: 80271
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering INBRIJA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2890459 | POUDRES PULMONAIRES DE DENSITE ULTRA BASSE (ULTRA LOW DENSITY PULMONARY POWDERS) | ⤷ Sign Up |
Austria | 357222 | ⤷ Sign Up | |
China | 1441670 | ⤷ Sign Up | |
Canada | 2444129 | METHODE ET DISPOSITIF D'INHALATION (INHALATION DEVICE AND METHOD) | ⤷ Sign Up |
China | 110833539 | 超低密度的肺部粉末 (Ultra low density pulmonary powders) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for INBRIJA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1613296 | 92782 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224 |
1613296 | CR 2015 00042 | Denmark | ⤷ Sign Up | PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |